The firm has reasons to believe that Edgewise’s ARCH study is not the study in question, highlighting that the letter states “objectionable conditions” at the clinical trial site between ...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders ...

Edgewise. “This confirmed our previous observations in the ARCH study of significant decreases in biomarkers of muscle damage and similarly we are seeing evidence of preservation of function in ...

Edgewise Networks will significantly improve the security of east-west communication by verifying the identity of application software, services and processes, Zscaler said. Zscaler has purchased ...

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent ...

Edgewise Therapeutics stock skyrocketed to a three-year high on Thursday after a single dose of its drug improved heart function in cardiomyopathy patients. Please watch the video at Investors.com ...

Edgewise Therapeutics (NASDAQ:EWTX) is building itself up as a good long-term biotech to hang onto. Especially, when you consider that it was able to report positive results from its phase 2 ...

Additionally, Edgewise is set to report significant data from its Phase 2 studies in Duchenne muscular dystrophy in the first half of 2025, which will further guide their Phase 3 planning.

We can readily understand why investors are attracted to unprofitable companies. For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the ...

Edgewise Chief Executive Officer ... of sevasemten in individuals with Becker based on findings from the DUNE and ARCH clinical trials, as well as provide perspec ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming ...